Business
CADTH Recommends Reimbursement for BioCryst’s ORLADEYO® (berotralstat) for the Routine Prevention of Attacks in Hereditary Angioedema Patients in Canada
INTENDED FOR CANADIAN AUDIENCES ONLY RESEARCH TRIANGLE PARK, N.C., March 08, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today
About this update from Biocryst Pharmaceuticals, Inc.
[{"type":"text","content":"INTENDED FOR CANADIAN AUDIENCES ONLY RESEARCH TRIANGLE PARK, N.C., March 08, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Canadian Agency for Drugs and Technologies in Health (CADTH) Canadian Drug Expert Committee (CDEC) has issued a positive recommendation for ORLADEYO® (berotralstat) to be reimbursed for the routine prevention of attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years of age and older. “We are still in need of additional options to help people living with HAE better manage their disease, despite the incredible progress we have made to date in addressing the treatment burden. Today’s announcement is a welcome one for the HAE community in Canada, as it should help increase access to this oral prophylactic treatment across our country,” said Daphne Dumbrille, on behalf of the HAE Canada Board of Directors. “As I have observed in my own practice, it is beneficial to have additional therapeutic options available to patients with HAE because each patient has an individualized treatment experience. In issuing this positive recommendation, CADTH is opening the door to many Canadian HAE patients being able to access ORLADEYO,” said Stephen Betschel, HBSc, MD, FRCPC, FAAAAI, Chair of the Canadian Hereditary Angioedema Network. “BioCryst is delighted that ORLADEYO has received this positive recommendation from CADTH. I am grateful to our team here at BioCryst and our many partners in the HAE community who underscored the value of ensuring Canadian patients have access to an oral, once-daily therapy for this rare, debilitating disease,” said Anand Janack, vice president and general manager of BioCryst Canada. Health Canada authorized ORLADEYO in June 2022 for the routine prevention of recurrent hereditary angioedema (HAE) attacks in patients 12 years and older. The full CADTH reimbursement recommendation for ORLADEYO is available on CADTH’s website. About ORLADEYO® (berotralstat)ORLADEYO® (berotralstat) is an oral therapy designed specifically to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years and older. One capsule of ORLADEYO per day works to prevent HAE attacks by decreasing the activity of plasma kallikrein. INDICATION1ORLADEYO® (berotralstat) is indicated for the routine prevention of attacks of heredit...